October « 2022 « Science and Enterprise

“Dark Genome” Drug Discoverer Gains $37M in Early Funds

By Alan, on October 19th, 2022%

Colorized scanning electron micrograph of a T lymphocyte. (NIAID)

19 Oct. 2022. A biotechnology enterprise discovering new drugs from non-protein coding regions of the genome is raising €37.5 million ($US 36.6 million) in venture funds. Nucleome Therapeutics Ltd. in Oxford, U.K. is a three year-old business spun-off from genetic research labs at University . . . → Read More: “Dark Genome” Drug Discoverer Gains $37M in Early Funds

Guide to Entering and Profiting in the World of Investments

By Alan, on October 19th, 2022%

By investing in a company, product, or venture, you are essentially betting that the future will be brighter than the present. . . . → Read More: Guide to Entering and Profiting in the World of Investments

Trial Shows Wearable Device Can Reduce Migraine

By Alan, on October 18th, 2022%

Results from a clinical trial show an electronic device worn on the arm can reduce migraine occurrences in people with history of the condition. . . . → Read More: Trial Shows Wearable Device Can Reduce Migraine

Three Tips for Starting as a Freelance Consultant

By Alan, on October 18th, 2022%

What does it take to be an effective freelance consultant? . . . → Read More: Three Tips for Starting as a Freelance Consultant

Tech Maintenance

By Alan, on October 17th, 2022%

Science & Enterprise’s parent company is undergoing a technology upgrade, so we won’t be publishing today. . . . → Read More: Tech Maintenance

Infographic – US Biotech Venture Funds Fall in Q3

By Alan, on October 15th, 2022%

Venture funds for U.S. biotechnology and pharmaceutical start-ups declined in the third quarter of 2022 from the 2021 record pace, but remain on track for historic highs. . . . → Read More: Infographic – US Biotech Venture Funds Fall in Q3

Trial Begins Testing RNA Hepatitis-B Treatment

By Alan, on October 14th, 2022%

A clinical trial is underway testing the safety and chemical activity of a hepatitis-B therapy using engineered RNA to block production of a key protein linked to the disease. . . . → Read More: Trial Begins Testing RNA Hepatitis-B Treatment

Hydrogel Biomaterials Company Raises $3M in Early Funds

By Alan, on October 13th, 2022%

A developer of bioactive hydrogels as alternatives to animal models for drug discovery and clinical lab tests is raising $3 million in its first venture round. . . . → Read More: Hydrogel Biomaterials Company Raises $3M in Early Funds

Start-Up to Manufacture, Supply Practical Radiation Drugs

By Alan, on October 12th, 2022%

A new company formed by a technology venture investor and the Mayo Clinic aims to produce and supply more readily available radiation drug therapies. . . . → Read More: Start-Up to Manufacture, Supply Practical Radiation Drugs

Gene Therapy Stimulates Missing Enzymes in Rare Disease

By Alan, on October 11th, 2022%

Results from a clinical trial show an experimental gene therapy for Krabbe disease is safe and produces enzymes missing in children with the rare disease. . . . → Read More: Gene Therapy Stimulates Missing Enzymes in Rare Disease

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise